Dapagliflozin CAS 461432-26-8
Dapagliflozin is a highly selective SGLT2 (sodium–glucose cotransporter 2) inhibitor used to improve glycemic control and protect kidney and cardiovascular function in patients with type 2 diabetes mellitus (T2DM). It has also become widely used for heart failure and chronic kidney disease management, giving it strong medical and commercial demand.
What is Dapagliflozin ?
Dapagliflozin cas 960404-48-2 is a first-in-class oral anti-diabetic drug that lowers blood glucose by promoting urinary glucose excretion.
Belonging to the gliflozin family, it is effective as monotherapy or in combination with other anti-diabetic agents.
Chemically, Dapagliflozin often exists in the form of dapagliflozin propanediol monohydrate, which offers enhanced stability and excellent pharmaceutical performance.
Technical Data
|
Item |
Detail |
|
Product |
Dapagliflozin / Dapagliflozin Propanediol Monohydrate |
|
CAS |
461432-26-8 (base) / 2112421-58-5 (propanediol monohydrate) |
|
Molecular Formula |
C21H25ClO6 |
|
Molecular Weight |
408.87 g/mol |
|
Appearance |
White / off-white powder |
|
Purity |
≥ 99% (HPLC) |
|
Grade |
Pharmaceutical / GMP |
|
Documents |
COA, MSDS, DMF, stability data available |
|
Storage |
2–8°C, protect from light |
Dapagliflozin Uses
Primary uses:
Type 2 diabetes mellitus (T2DM)
Chronic kidney disease (CKD)
Heart failure with reduced or preserved ejection fraction
Reduction of cardiovascular risks in diabetic adults
Emerging research applications:
Diabetic nephropathy
Obesity & metabolic syndrome
Combination therapy in weight-management programs
Benefits of Dapagliflozin
|
Category |
Benefit |
|
Glycemic control |
Reduces HbA1c and fasting glucose |
|
Body weight |
Promotes weight loss |
|
Cardiovascular |
Decreases risk of hospitalization for heart failure |
|
Renal |
Slows CKD progression and proteinuria |
|
Combination therapy |
Works safely with metformin, insulin, GLP-1 agonists |
Due to its multi-system protection, Dapagliflozin has become one of the most widely adopted SGLT2 inhibitors globally, with increasing demand from hospitals, pharmacies, and pharmaceutical manufacturers.
Dapagliflozin Applications
Dapagliflozin selectively inhibits SGLT2 in the renal proximal tubule, reducing glucose reabsorption and increasing glucose excretion through urine.
|
Action |
Result |
|
Blocks renal glucose reabsorption |
Lowers blood glucose |
|
Promotes calorie loss via urine |
Supports weight reduction |
|
Reduces renal hyperfiltration |
Protects kidney function |
|
Decreases cardiac workload |
Benefits heart failure patients |
Dapagliflozin Side Effects
Dapagliflozin is well-tolerated overall, but possible side effects include:
|
Common |
Infrequent |
|
Increased urination |
Hypotension |
|
Urinary tract infection |
Ketoacidosis (rare) |
|
Genital yeast infection |
Acute kidney injury (rare) |
|
Thirst |
Dehydration |
Most dapagliflozin side effects are mild and manageable, especially with proper hydration and monitoring.
Hottags：
dapagliflozin API, dapagliflozin bulk supply, dapagliflozin API price, dapagliflozin manufacturer, dapagliflozin supplier, dapagliflozin exporter, dapagliflozin wholesale, dapagliflozin GMP grade, dapagliflozin DMF support, dapagliflozin FDA filing, dapagliflozin in stock, dapagliflozin factory China, dapagliflozin custom synthesis, dapagliflozin COA MSDS DMF
Message us to get your personalized quotation within 24 hours.
-
Whatsapp:+852 6736 4057
-
Telegram:@hinovopept
-
Email:novopept@gmail.com
Hot Tags: dapagliflozin cas 461432-26-8, China dapagliflozin cas 461432-26-8 manufacturers, suppliers, factory
Send Inquiry
